Actions of adenosine at its receptors in the CNS: Insights from knockouts and drugs

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 385-412

  Fredholm, Bertil B ^a   Chen, Jiang Fan ^b   Masino, Susan A ^c   Vaugeois, Jean Marie ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TRINITY COLLEGE   (United States)

^d UNIVERSITÉ DE ROUEN   (France)

Author keywords

A1 receptor; A2A receptor; Caffeine; Ischemia; Pain; Parkinson's disease

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; CAFFEINE; DOPAMINE; DOPAMINE 2 RECEPTOR; PSYCHOSTIMULANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; GABAERGIC TRANSMISSION; GENE DELETION; HETEROZYGOTE; HUNTINGTON CHOREA; MOUSE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; POSTSYNAPTIC INHIBITION; PREPULSE INHIBITION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SPERMATOZOON CAPACITATION; STRAIN DIFFERENCE; THROMBOCYTE AGGREGATION;

ADENOSINE; ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; MICE; MICE, KNOCKOUT; NERVOUS SYSTEM DISEASES; RECEPTORS, PURINERGIC P1;

ANIMALIA;

EID: 13844315635     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.095731     Document Type: Review

References (157)

1. Fredholm BB. 1996. Adenosine and neuroprotection. In Neuroprotective Agents and Cerebral Ischemia, ed. AR Green, AJ Cross, pp. 259-80. London: Academic
2. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. 1999. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59:355-96
3. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau E. 1999. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51:83-153
4. Cunha RA. 2001. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem. Int. 38:107-25
5. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. 2000. Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:364-74
6. Dunwiddie TV, Masino SA. 2001. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 24:31-55
7. Fredholm BB, IJzerman AP, Jacobson KA, Klotz K-N, Linden J. 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:527-52
8. Linden J. 2001. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol. 41:775-87
9. Latini S, Pedata F. 2001. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem. 79:463-84
10. Dalpiaz A, Manfredini S. 2002. Adenosine A(1) receptor: analysis of the potential therapeutic effects obtained by its activation in the central nervous system. Curr. Med. Chem. 9:1923-37
11. Fredhohn BB. 2002. Adenosine receptors. In Understanding G Protein-Coupled Receptors and Their Role in the CNS, ed. MN Pangalos, CH Davies, pp. 191-204. Oxford: Oxford Univ. Press
12. Rorke S, Holgate ST. 2002. Targeting adenosine receptors: novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Med. 1:99-105
13. Thong FS, Graham TE. 2002. The putative roles of adenosine in insulin- and exercise-mediated regulation of glucose transport and glycogen metabolism in skeletal muscle. Can. J. Appl. Physiol. 27:152-78
14. Klinger M, Freissmuth M, Nanoff C. 2002. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell. Signal. 14:99-108
15. Schwarzschild MA, Chen JF, Ascherio A. 2002. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 58:1154-60
16. Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN. 2003. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2:366-74
17. Sawynok J, Liu XJ. 2003. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog. Neurobiol. 69:313-40
18. Chen JF. 2003. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment. Drug News Perspect. 16:597-604
19. Fredholm BB, Svenningsson P. 2003. Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology 61:S5-9
20. Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L. 2003. Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr. Top. Med. Chem. 3:369-85
21. Headrick JP, Hack B, Ashton KJ. 2003. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am. J. Physiol. Heart Circ. Physiol. 285:H1797-818
22. Schulte G, Fredholm BB. 2003. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell. Signal. 15:813-27
23. Blackburn MR. 2003. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol. Sci. 24:66-70
24. 2A receptors and therapeutic applications. Curr. Top. Med. Chem. 3:413-26
25. Haskó G, Cronstein BN. 2004. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25:33-39
26. McCallion K, Harkin DW, Gardiner KR. 2004. Role of adenosine in immunomodulation: review of the literature. Crit. Care Med. 32:273-77
27. 1 receptor. Proc. Natl. Acad. Sci. USA 98:9407-12
28. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, et al. 2001. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc. Natl. Acad. Sci. USA 98:9983-88
29. Minelli A, Liguori L, Bellazza I, Mannucci R, Johansson B, Fredhohn BB. 2004. Involvement of A1 adenosine receptors in the acquisition of fertilizing capacity. J. Androl. 25:286-92
30. 1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur. J. Neurosci. 16:547-50
31. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, et al. 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature 388:674-78
32. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, et al. 1999. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19:9192-200
33. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, et al. 2003. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest. 112:883-91
34. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. 2000. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275:4429-34
35. Cerniway RJ, Yang Z, Jacobson MA, Linden J, Matherne GP. 2001. Targeted deletion of A(3) adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. Am. J. Physiol. Heart Circ. Physiol. 281:H1751-58
36. Avila MY, Stone RA, Civan MM. 2002. Knockout of A3 adenosine receptors reduces mouse intraocular pressure. Invest. Ophthalmol. Vis. Sci. 43:3021-26
37. Rivkees SA, Thevananther S, Hao H. 2000. Are A3 adenosine receptors expressed in the brain? NeuroReport 11:1025-30
38. Scammell TE, Arrigoni E, Thompson MA, Ronan PJ, Saper CB, Greene RW. 2003. Focal deletion of the adenosine A1 receptor in adult mice using an adeno-associated viral vector. J. Neurosci. 23:5762-70
39. Boison D, Scheurer L, Zumsteg V, Rülicke T, Litynski P, et al. 2002. Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proc. Natl. Acad. Sci. USA 99:6985-90
40. Lecoq K, Belloc I, Desgranges C, Daignan-Fornier B. 2001. Role of adenosine kinase in Saccharomyces cerevisiae: identification of the ADO1 gene and study of the mutant phenotypes. Yeast 18:335-42
41. Riksen NP, Rongen GA, Blom HJ, Russel FG, Boers GH, Smits P. 2003. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc. Res. 59:271-76
42. Blackburn MR, Datta SK, Kellems RE. 1998. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J. Biol. Chem. 273:5093-100
43. Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV. 2001. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J. Clin. Invest. 108:131-41
44. Van De Wiele CJ, Vaughn JG, Blackburn MR, Ledent CA, Jacobson M, et al. 2002. Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation. J. Clin. Invest. 110:395-402
45. Jin X, Shepherd RK, Duling BR, Linden J. 1997. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J. Clin. Invest. 100:2849-57
46. Tilley SL, Wagoner VA, Salvatore CA, Jacobson MA, Koller BH. 2000. Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. J. Clin. Invest. 105:361-67
47. Fredholm BB, Irenius E, Kull B, Schulte G. 2001. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol. 61:443-48
48. Gomez G, Sitkovsky MV. 2003. Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 102:4472-78
49. Haskó G, Sitkovsky MV, Szabó C. 2004. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol. Sci. 25:152-57
50. Ohno M, Frankland PW, Chen AP, Costa RM, Silva AJ. 2001. Inducible, pharmacogenetic approaches to the study of learning and memory. Nat. Neurosci. 4:1238-43
51. Chapman PF. 2002. Giving drugs to knockout mice: Can they do that? Trends Neurosci. 25:277-79
52. Armstrong JM, Chen JF, Schwarzschild MA, Apasov S, Smith PT, et al. 2001. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem. J. 354:123-30
53. Kühn R, Schwenk F, Aguet M, Rajewsky K. 1995. Inducible gene targeting in mice. Science 269:1427-29
54. Mayford M, Kandel ER. 1999. Genetic approaches to memory storage. Trends Genet. 15:463-70
55. Iwasato T, Datwani A, Wolf AM, Nishiyama H, Taguchi Y, et al. 2000. Cortex-restricted disruption of NMDAR1 impairs neuronal patterns in the barrel cortex. Nature 406:726-31
56. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, et al. 1995. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269:230-34
57. Gerlai R. 1996. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci. 19:177-81
58. Schauwecker PE, Steward O. 1997. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc. Natl. Acad. Sci. USA 94:4103-8
59. Schweda F, Wagner C, Krämer BK, Schnermann J, Kurtz A. 2003. Preserved macula densa-dependent renin secretion in A1 adenosine receptor knockout mice. Am. J. Physiol. Renal Physiol. 284:F770-77
60. Wolfer DP, Crusio WE, Lipp HP. 2002. Knockout mice: simple solutions to the problems of genetic background and flanking genes. Trends Neurosci. 25:336-40
61. Moore KA, Nicoll RA, Schmilz D. 2003. Adenosine gates synaptic plasticity at hippocampal mossy fiber synapses. Proc. Natl. Acad. Sci. USA 100:14397-402
62. 1 receptors. J. Pharmacol. Exp. Ther. 303:356-63
63. 1 receptor inhibition. Neuroscience 112:319-29
64. Dunwiddie TV, Diao LH, Kim HO, Jiang JL, Jacobson KA. 1997. Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. J. Neurosci. 17:607-14
65. 1 receptors. Drug Dev. Res. 58:428-38
66. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. 1992. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci. 13:439-45
67. 1 receptor knockout mice. Presented at Annu. Meet. Soc. Neurosci., 32nd, pp. 549-10, Orlando, FL
68. 1 receptor gene deletion in neuronal damage following global cerebral ischemia in mouse in vivo and in vitro. Eur. J. Neurosci. 20:1197-204
69. Turner CP, Seli M, Ment L, Stewart W, Yan H, et al. 2003. A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc. Natl. Acad. Sci. USA 100:11718-22
70. Bona E, Ådén U, Fredhohn BB, Hagberg H. 1995. The effect of long term caffeine treatment on hypoxic-ischemic brain damage in the neonate. Pediatr. Res. 38:312-18
71. 2A knockout mice. Stroke 34:739-44
72. 2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat. Med. In press
73. Guo Y, Bolli R, Bao W, Wu WJ, Black RG, et al. 2001. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J. Mol. Cell. Cardiol. 33:825-30
74. Harrison GJ, Cerniway RJ, Peart J, Berr SS, Ashton K, et al. 2002. Effects of A(3) adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart. Cardiovasc. Res. 53:147-55
75. Fedorova IM, Jacobson MA, Basile A, Jacobson KA. 2003. Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell. Mol. Neurobiol. 23:431-47
76. El Yacoubi M, Ledent C, Menard JF, Parmentier M, Costentin J, Vaugeois JM. 2000. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br. J. Pharmacol. 129:1465-73
77. Dassesse D, Ledent C, Parmentier M, Schiffmann SN. 2001. Acute and chronic caffeine administration differentially alters striatal gene expression in wild-type and adenosine A(2A) receptor-deficient mice. Synapse 42:63-76
78. 2A receptors. Neuropharmacology 46:1008-17
79. Porkka-Heiskanen T, Alanko L, Kalinchuk A, Stenberg D. 2002. Adenosine and sleep. Sleep Med. Rev. 6:321-32
80. Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW. 1997. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 276:1265-68
81. Alanko L, Heiskanen S, Stenberg D, Porkka-Heiskanen T. 2003. Adenosine kinase and 5′-nucleotidase activity after prolonged wakefulness in the cortex and the basal forebrain of rat. Neurochem. Int. 42:449-54
82. Mackiewicz M, Nikonova EV, Zimmerman JE, Galante RJ, Zhang L, et al. 2003. Enzymes of adenosine metabolism in the brain: diurnal rhythm and the effect of sleep deprivation. J. Neurochem. 85:348-57
83. Ticho SR, Radulovacki M. 1991. Role of adenosine in sleep and temperature regulation in the preoptic area of rats. Pharmacol. Biochem. Behav. 40:33-40
84. 1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. Brain Res. 692:79-85
85. Virus RM, Ticho S, Pilditch M, Radulovacki M. 1990. A comparison of the effects of caffeine, 8-cyclopentyltheophylline, and alloxazine on sleep in rats. Possible roles of central nervous system adenosine receptors. Neuropsychopharmacology 3:243-49
86. Rainnie DG, Grunze HCR, McCarley RW, Greene RW. 1994. Adenosine inhibition of mesopontine cholinergic neurons: implications for EEG arousal. Science 263:689-92
87. Chamberlin NL, Arrigoni E, Chou TC, Scammell TE, Greene RW, Saper CB. 2003. Effects of adenosine on gabaergic synaptic inputs to identified ventrolateral preoptic neurons. Neuroscience 119:913-18
88. Thakkar MM, Winston S, McCarley RW. 2002. Orexin neurons of the hypothalamus express adenosine A1 receptors. Brain Res. 944:190-94
89. Thakkar MM, Winston S, McCarley RW. 2003. A1 receptor and adenosinergic homeostatic regulation of sleepwakefulness: effects of antisense to the A1 receptor in the cholinergic basal forebrain. J. Neurosci. 23:4278-87
90. Stenberg D, Litonius E, Halldner L, Johansson B, Fredholm BB, Porkka-Heiskanen T. 2003. Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor. J. Sleep Res. 12:283-90
91. Koos BJ, Maeda T, Jan C. 2001. Adenosine A(1) and A(2A) receptors modulate sleep state and breathing in fetal sheep. J. Appl. Physiol. 91:343-50
92. Scammell TE, Gerashchenko DY, Mochizuki T, McCarthy MT, Estabrooke IV, et al. 2001. An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neuroscience 107:653-63
93. 2A receptor mRNA in the rat following sleep deprivation. NeuroReport 12:1577-80
94. Urade Y, Eguchi N, Qu WM, Sakata M, Huang ZL, et al. 2003. Sleep regulation in adenosine A2A receptor-deficient mice. Neurology 61:S94-96
95. olf in rat striatum. Mol. Pharmacol. 58:771-7
96. Hervé D, Le Moine C, Corvol JC, Belluscio L, Ledent C, et al. 2001. Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J. Neurosci. 21:4390-99
97. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K. 1997. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:482-87
98. Svenningsson P, Fourreau L, Bloch B, Fredholm BB, Gonon F, Le Moine C. 1999. Opposite tonic modulation of dopamine and adenosine on c-fos mRNA expression in striatopallidal neurons. Neuroscience 89:827-37
99. 2 receptors. J. Neurosci. 20:5949-57
100. Dassesse D, Massie A, Ferrari R, Ledent C, Parmentier M, et al. 2001. Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J. Neurochem. 78:183-98
101. Chen JF, Beilstein M, Xu YH, Turner TJ, Moratalla R, et al. 2000. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 97:195-204
102. Rimondini R, Ferré S, Ögren SO, Fuxe K. 1997. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17:82-91
103. 2A receptors. Proc. Natl. Acad. Sci. USA 97:1856-60
104. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, et al. 2001. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc. Natl. Acad. Sci. USA 98:1970-75
105. Aoyama S, Kase H, Borrelli E. 2000. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J. Neurosci. 20:5848-52
106. Berrendero F, Castañé A, Ledent C, Parmentier M, Maldonado R, Valverde O. 2003. Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1/A2a double knockout mice. Eur. J. Neurosci. 17:315-24
107. Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, et al. 2003. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology 61:S55-61
108. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, et al. 2000. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674-79
109. Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, et al. 2001. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50:56-63
110. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. 2003. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60:790-95
111. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, et al. 2001. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21:RC143
112. Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. 2002. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80:262-70
113. Alfinito PD, Wang SP, Manzino L, Rijhsinghani S, Zeevalk GD, Sonsalla PK. 2003. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J. Neurosci. 23:10982-87
114. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM. 2001. Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy. NeuroReport 12:983-86
115. Moo-Puc RE, Góngora-Alfaro JL, Alvarez-Cervera FJ, Pineda JC, Arankowsky-Sandoval G, Heredia-López F. 2003. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Neuropharmacology 45:493-503
116. Hauser RA, Hubble JP, Truong DD. 2003. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61:297-303
117. Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, et al. 2003. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61:293-96
118. Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, et al. 2002. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J. Neurosci. 22:1054-62
119. Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, et al. 2003. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184:285-94
120. Blum D, Galas MC, Pintor A, Brouillet E, Ledent C, et al. 2003. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 23:5361-69
121. Fink JS, Kalda A, Ryu H, Stack EC, Schwarzschild MA, et al. 2004. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J. Neurochem. 88:538-44
122. Popoli P, Frank C, Tebano MT, Potenza RL, Pintor A, et al. 2003. Modulation of glutamate release and excitotoxicity by adenosine A2A receptors. Neurology 61:S69-71
123. Wang JH, Short J, Ledent C, Lawrence AJ, Buuse M. 2003. Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behav. Brain Res. 143:201-7
124. Ferré S. 1997. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 133:107-20
125. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM. 2003. Caffeine reduces hypnotic effects of alcohol through adenosine A2A receptor blockade. Neuropharmacology 45:977-85
126. El Yacoubi M, Ledent C, Parmentier M, Daoust M, Costentin J, Vaugeois J-M. 2001. Absence of the adenosine A(2A) receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. Neuropharmacology 40:424-32
127. Naassila M, Ledent C, Daoust M. 2002. Low ethanol sensitivity and increased ethanol consumption in mice lacking adenosine A2A receptors. J. Neurosci. 22:10487-93
128. Diamond I, Gordon AS. 1994. The role of adenosine in mediating cellular and molecular responses to ethanol. Suppl. Exp. 71:175-83
129. Gouder N, Scheurer L, Fritschy JM, Boison D. 2004. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J. Neurosci. 24:692-701
130. Huber A, Padrun V, Déglon N, Aebischer P, Möhler H, Boison D. 2001. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc. Natl. Acad. Sci. USA 98:7611-16
131. Boison D, Huber A, Padrun V, Déglon N, Aebischer P, Möhler H. 2002. Seizure suppression by adenosine-releasing cells is independent of seizure frequency. Epilepsia 43:788-96
132. Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, et al. 2004. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J. Neurosci. 24:1521-29
133. 3 receptors in microglia cells. J. Neurochem. 86:1051-54
134. Lang UE, Lang F, Richter K, Vallon V, Lipp HP, et al. 2003. Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behav. Brain Res. 145:179-88
135. de Mendonça A, Ribeiro JA. 1997. Adenosine and neuronal plasticity. Life Sci. 60:245-51
136. Almeida T, Rodrigues RJ, de Mendonça A, Ribeiro JA, Cunha RA. 2003. Purinergic P2 receptors trigger adenosine release leading to adenosine A2A receptor activation and facilitation of long-term potentiation in rat hippocampal slices. Neuroscience 122:111-21
137. d'Alcantara P, Ledent C, Swillens S, Schiffmann SN. 2001. Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 107:455-64
138. Schiffmann SN, Dassesse D, d'Alcantara P, Ledent C, Swillens S, Zoli M. 2003. A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission. Neurology 61:S24-29
139. Millan MJ. 2003. The neurobiology and control of anxious states. Prog. Neurobiol. 70:83-244
140. Boulenger JP, Uhde TW, Wolff EA, Post RM. 1984. Increased sensitivity to caffeine in patients with panic disorders. Arch. Gen. Psychiatry 41:1067-71
141. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM. 2000. The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists. Psychopharmacology 148:153-63
142. Imaizumi M, Miyazaki S, Onodera K. 1994. Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors. Methods Find. Exp. Clin. Pharmacol. 16:639-44
143. Jain N, Kemp N, Adeyemo O, Buchanan P, Stone TW. 1995. Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol. 116:2127-33
144. Florio C, Prezioso A, Papaioannou A, Vertua R. 1998. Adenosine A1 receptors modulate anxiety in CD1 mice. Psychopharmacology 136:311-19
145. Alsene K, Deckert J, Sand P, de Wit H. 2003. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28:1694-702
146. Hamilton SP, Slager SL, De Leon AB, Heiman GA, Klein DF, et al. 2004. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 29:558-65
147. Jégou S, El Yacoubi M, Mounien L, Ledent C, Parmentier M, et al. 2003. Adenosine A2A receptor gene disruption provokes marked changes in melanocortin content and pro-opiomelanocortin gene expression. J. Neuroendocrinol. 15:1171-77
148. Navarro JF, Romero C, Maldonado E. 2000. Effects of N6-cyclohexyl adenosine (CHA) on isolation-induced aggression in male mice. Methods Find. Exp. Clin. Pharmacol. 22:43-46
149. El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, et al. 2001. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br. J. Pharmacol. 134:68-77
150. Wu WP, Hao JX, Halldner-Henriksson L, Xu XJ, Jacobson MA, et al. 2002. Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors. Neuroscience 114:523-27
151. 2A receptor knockout mice. Br. J. Pharmacol. 141:1006-14
152. 1 receptors in hippocampus. Naunyn. Schmiedeberg's Arch. Pharmacol. In press
153. Chen JF, Steyn S, Staal R, Petzer JP, Xu K, et al. 2002. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J. Biol. Chem. 277:36040-44
154. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, et al. 1998. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43:507-13
155. Grondin R, Bédard PJ, Hadj Tahar A, Grégoire L, Mori A, Kase H. 1999. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673-77
156. Blum D, Gall D, Galas MC, d'Alcantara P, Bantubungi K, Schiffmann SN. 2002. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 22:9122-33
157. Dall'Igna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR. 2003. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br. J. Pharmacol. 138:1207-9